RHYTHM PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Available-for-sale Securities, Amortized Cost Basis of $113.99 million as of 2017-12-31, per its 8-K filed 2018-11-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-11-09
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $113.99M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $2.50M.
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $4.00M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $113.99M 8-K · filed 2018-11-09 |
| 2017-09-30 | $2.50M 10-Q · filed 2017-11-14 |
| 2016-12-31 | $4.00M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |